Press Release
May 11, 2022

Nuvig Announces $47 Million Series A Financing and Launches to Develop Novel Immune Therapeutics for Chronic Inflammatory and Autoimmune Diseases

The Life Sciences team advised Nuvig Therapeutics in its $47 million Series A financing and the launch of the company to develop novel therapeutics that induce mechanisms of immune homeostasis and treat autoimmune diseases without compromising normal immune function.

Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients.

The round was led by Novo Holdings A/S and Platanus, and joined by Bristol Myers Squibb, Digitalis Ventures, and Mission BioCapital.

The Goodwin team was led by Steven Green, Kingsley Taft, Mulon Luo, Carolyn Nguyen, Jacob Osborn, and Godze Guckaya.

For more details, read the press release and articles in Endpoints, BioSpace, and Fierce Biotech.